Optic atrophy after cabazitaxel treatment in a patient with castration-resistant prostate cancer: a case report

2018 ◽  
Vol 64 (2) ◽  
pp. 71-73 ◽  
Author(s):  
Sevda Diker ◽  
Ömer Diker
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Case Report ◽  
Adverse Effects ◽  
Optic Neuropathy ◽  
Optic Atrophy ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Anti Cancer ◽  
New Generation

Taxanes are a group of cytotoxic anti-cancer agents used in the treatment of solid tumours. The neurotoxic adverse effects of docetaxel and paclitaxel, including optic neuropathy, are well known. Cabazitaxel is a new generation taxane showing lesser drug resistance when compared with previous ones. Optic atrophy due to the use of cabazitaxel has not been previously reported. Herein, we report a patient with prostate cancer who developed optic atrophy after cabazitaxel treatment.

AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer

2018 ◽  
Vol 18 (9) ◽  
pp. 869-876
Author(s):  
Samanta Salvi ◽  
Vincenza Conteduca ◽  
Cristian Lolli ◽  
Sara Testoni ◽  
Valentina Casadio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Copy Number ◽  
Clinical Trial Design ◽  
Complete Information ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Anti Cancer ◽  
Hormone Sensitive ◽  
Predictive And Prognostic Biomarker

Background: Adaptive upregulation of Androgen Receptor (AR) is the most common event involved in the progression from hormone sensitive to Castration-Resistant Prostate Cancer (CRPC). AR signaling remains the main target of new AR signalling-directed therapies such as abiraterone and enzalutamide in CRPC patients. Objective: In this review, we discuss general mechanisms of resistance to AR-targeted therapies, with a focus on the role of AR Copy Number (CN). We reported methods and clinical applications of AR CN evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker. Conclusion: Outcomes of CRPC patients are reported to be highly variable as the consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.

Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report

2016 ◽  
Vol 14 (5) ◽  
pp. e529-e533 ◽  
Author(s):  
Giuseppe De Vincentis ◽  
Giulia Anna Follacchio ◽  
Viviana Frantellizzi ◽  
Mauro Liberatore ◽  
Francesco Monteleone ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Flare Phenomenon ◽  
Castration Resistant

Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report

2019 ◽  
Vol 17 (1) ◽  
pp. e61-e64 ◽  
Author(s):  
Aline Bobato Lara Gongora ◽  
Felipe Sales Nogueira Amorim Canedo ◽  
André Luis Alves de Melo ◽  
Regis Otaviano Franca Bezerra ◽  
Paula Fontes Asprino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Brca2 Mutation ◽  
Tumor Lysis Syndrome ◽  
Castration Resistant Prostate Cancer ◽  
Tumor Lysis ◽  
Castration Resistant ◽  
Platinum Based Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document